Arkansas court tosses $1.2-billion judgment against J&J
LITTLE ROCK, Ark. — The Arkansas Supreme Court on Thursday overturned a $1.2-billion judgment against Johnson & Johnson in a lawsuit challenging the drug maker’s marketing of the antipsychotic drug Risperdal.
The court ruled that the state improperly sued under a law that applies to healthcare facilities, not pharmaceutical companies.
The ruling comes in an appeal of a lawsuit filed by Arkansas against the drug maker and subsidiary Janssen Pharmaceuticals. The state says the companies didn’t properly communicate the drug’s risks and marketed it for off-label use, calling the practices fraudulent.
Johnson & Johnson said there was no fraud and Arkansas’ Medicaid program wasn’t harmed.
Risperdal and similar antipsychotic drugs have been linked to increased risk of strokes and death in elderly patients, along with seizures, weight gain and diabetes.
Risperdal was introduced in 1994 as a “second-generation” antipsychotic drug — and it earned Johnson & Johnson billions of dollars in sales before generic versions became available. The drug is used to treat schizophrenia, bipolar disorder and irritability in autism patients.
Arkansas Atty. Gen. Dustin McDaniel sued the companies in 2007, arguing that they downplayed and concealed risks of the drug and lied to doctors for years about its side effects. The case is among numerous lawsuits making similar claims.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
